Targacept to Retain Full Rights for TC-5619

by Benzinga Staff
May 2, 2011 7:55 AM | 12 seconds read |
Targacept, Inc. TRGT today announced that AstraZeneca will not exercise its option to license Targacept's product candidate TC-5619. As a result, Targacept retains full rights to the compound, a highly selective alpha7 neuronal nicotinic receptor modulator.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: NewsFDABiotechnologyHealth Care
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!